{"id":"expanded-antimicrobial-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Drug interactions"},{"rate":null,"effect":"Organ toxicity (hepatic, renal)"},{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL2368688","moleculeType":"Small molecule","molecularWeight":"571.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach involves the concurrent or sequential use of multiple antimicrobial drugs with different mechanisms of action and spectrum coverage to address polymicrobial infections or infections with uncertain etiology. The strategy aims to improve clinical outcomes by ensuring adequate coverage of likely pathogens while minimizing the development of antimicrobial resistance through combination therapy.","oneSentence":"Expanded antimicrobial therapy uses a broadened spectrum of antimicrobial agents to treat infections caused by multiple pathogenic organisms simultaneously.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:31.551Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Polymicrobial infections"},{"name":"Empiric treatment of severe infections with uncertain etiology"}]},"trialDetails":[{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Sepsis, Tuberculosis","enrollment":344},{"nctId":"NCT05534399","phase":"NA","title":"Antibiotic Strategy and Asymptomatic Bacteriuria in the Context of Intra-vesical Botulinum Toxin A Injections.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2026-05","conditions":"Urinary Tract Disease","enrollment":526},{"nctId":"NCT06383611","phase":"","title":"Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Osteal Therapeutics, Inc.","startDate":"","conditions":"Prosthetic-joint Infection","enrollment":""},{"nctId":"NCT06890676","phase":"NA","title":"Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control","status":"RECRUITING","sponsor":"Missouri Department of Health and Senior Services","startDate":"2024-03-01","conditions":"Periodontitis, Gingivitis, Periodontal Disease","enrollment":150},{"nctId":"NCT06879184","phase":"","title":"Cohort of the Specialist Network Infectious Diseases","status":"NOT_YET_RECRUITING","sponsor":"Goethe University","startDate":"2025-03-20","conditions":"Infectious Diseases and Manifestations","enrollment":15000},{"nctId":"NCT05093166","phase":"PHASE1, PHASE2","title":"Clinical Trial to Assess the Safety and Efficacy of Investigational Product in Patients Due to Hypospadias Treatment Failure","status":"TERMINATED","sponsor":"Holostem s.r.l.","startDate":"2021-11-26","conditions":"Hypospadias","enrollment":1},{"nctId":"NCT06422533","phase":"NA","title":"Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2023-11-07","conditions":"Hematologic Neoplasms, Neutropenia","enrollment":226},{"nctId":"NCT04597242","phase":"","title":"Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia","status":"NO_LONGER_AVAILABLE","sponsor":"ContraFect","startDate":"","conditions":"MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis","enrollment":""},{"nctId":"NCT03526185","phase":"EARLY_PHASE1","title":"A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes","status":"TERMINATED","sponsor":"Yale University","startDate":"2018-02-06","conditions":"Metastatic Melanoma","enrollment":6},{"nctId":"NCT03490331","phase":"PHASE1, PHASE2","title":"Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)","status":"TERMINATED","sponsor":"Holostem s.r.l.","startDate":"2018-03-19","conditions":"Junctional Epidermolysis Bullosa","enrollment":1},{"nctId":"NCT02984085","phase":"PHASE1, PHASE2","title":"Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.","status":"TERMINATED","sponsor":"Holostem s.r.l.","startDate":"2017-01-30","conditions":"Recessive Dystrophic Epidermolysis Bullosa","enrollment":3},{"nctId":"NCT04513821","phase":"","title":"Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI","status":"AVAILABLE","sponsor":"Leonard-Meron Biosciences, Inc.","startDate":"","conditions":"Catheter-Related Infections","enrollment":""},{"nctId":"NCT04135183","phase":"NA","title":"Assessing Effectiveness of Community Acquired Pneumonia Treatment by Continuous Pneumonia Severity Score","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-07-01","conditions":"Community-acquired Pneumonia","enrollment":2000},{"nctId":"NCT01081808","phase":"PHASE1","title":"Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors","status":"TERMINATED","sponsor":"Roger Williams Medical Center","startDate":"2009-10","conditions":"Neoplasms, Tumors, Solid Tumors","enrollment":2},{"nctId":"NCT02148016","phase":"PHASE1, PHASE2","title":"Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2012-12","conditions":"Corneal Disease, Pterygium, Myopia","enrollment":30},{"nctId":"NCT01779518","phase":"","title":"Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C","status":"APPROVED_FOR_MARKETING","sponsor":"Gilead Sciences","startDate":"","conditions":"Post-transplant Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":238,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Expanded antimicrobial therapy","genericName":"Expanded antimicrobial therapy","companyName":"University of Virginia","companyId":"university-of-virginia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Expanded antimicrobial therapy uses a broadened spectrum of antimicrobial agents to treat infections caused by multiple pathogenic organisms simultaneously. Used for Polymicrobial infections, Empiric treatment of severe infections with uncertain etiology.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}